Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Shareholder Meeting (August 2022)
17 slides from Aroa Biosurgery's shareholder meeting presentation, Aug 10, 2022
Slide 1: Aroa Biosurgery AGM August 2022 CEO's Report
For personal use only Aroa Biosurgery AGM AUGUST 2022 CEO’S REPORT Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 10 August 2022 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). For personal use only Information in this Presentation The information in this Present
Slide 3: FY22 metrics at a glance
|3 FY22 metrics at a glance For personal use only NZ$39.2m AROA Direct 84% increase in product sales Sales 36 US FY21 on constant currency basis NZ$14.3m up from NZ$10.5m Salespeople1 in FY21 72 Active Sales to TELA 76% GM Myriad™ Accts2 Bio 8% improvement in product Up from 16 in FY21 (350%) NZ$24.
Slide 4: AROA ECM – Structure & Biology for Regenerative Healing
|4 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach For personal use only
Slide 5: Substantial Growth Opportunities > $2.5B TAM
|5 Substantial Growth Opportunities > $2.5B1 TAM For personal use only Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure U
Slide 6: Strategy
For personal use only Strategy
Slide 7: Strategic Overview
|7 Strategic Overview For personal use only Products that deliver a step change in healing outcomes and value Vision Ensure a safe, healthy, and To become a world leading regenerative productive healing company workplace A pipeline of next- generation regenerative technologies Mitigate AROA’s impact
Slide 8: Product Platforms
|8 Product Platforms Combinations of AROA ECM products & Enivo For personal use only Efficacy potential to deliver a step change in healing outcomes AROA ECM Enivo Devices for a Treatment to wide range of enable tissue tissue apposition regeneration Standard applications of Care t High-level graphic
Slide 9: FY23 Execution
For personal use only FY23 Execution
Slide 10: Myriad
| 10 Myriad For personal use only Ongoing salesforce expansion: targeting ~40 field salespeople by end of FY23 Salesforce productivity: continuous improvement & verify that the sales model is scalable Myriad - MASTRR Clinical Registry : targeting 300 patients across ten US sites over a three-year pe
Slide 11: Symphony
| 11 Symphony For personal use only Soft launch in US Veterans Affairs: Early clinical experience, modest sales, set up for FY24 US reimbursement changes for ‘Skin Substitutes’: CMS targeting changes in physician’s office in 2024, Hospital Outpatient TBD. Impacts future sales & pricing strategy Symp
Slide 12: OviTex & OviTex PRS
| 12 OviTex & OviTex PRS For personal use only OviTex, OviTex LPR & PRS continue to gain momentum. TELA Bio sales guidance of US$40- 45m in CY22 up from US$29.5m in CY21 Bravo I (ventral hernia): 92 patients, 2.6% recurrence rate in ventral hernias at 24-months Bravo II (robotic ) 157 inguinal herni
Slide 13: Endoform
| 13 Endoform For personal use only Modest growth : serviced by virtual inside sales team Clinical evidence: Targeting completion of Venous Leg Ulcer real-world study by Mar’ 23
Slide 14: Enivo
| 14 Enivo For personal use only Design locked & completing testing for US FDA submission: targeting confirmation of 510k or DeNovo by mid CY23 US Total Addressable Market Preclinical model demonstrates treatment >$1B efficacy: targeting Peer-reviewed publication (AROA management estimate) Sept’ 22
Slide 15: FY23 Catalysts & Milestones
| 15 FY23 Catalysts & Milestones For personal use only Post-COVID AROA Sales TELA Bio Sales Momentum Momentum COVID-19 expected to have a reduced impact through CY22 Clinical outcomes & cost savings Fully dedicated driving increasing adoption field sales team. Myriad expected to drive growth. Clinic
Slide 16: FY23 Guidance
| 16 FY23 Guidance1 For personal use only Forecast Product Sales Forecast Gross Margin Cash Balance NZ$51-55m 77% NZ$40-45m 1. Given the dynamic and evolving impact of COVID-19, guidance is subject to no material decline in US medical procedure numbers or sustained disruption to AROA’s manufacturing
Slide 17: Thank you for attending
For personal use only Thank you for attending CONTACTS Simon Hinsley Matt Wright Investor Relations Media m +61 401 809 653 m +61 451 896 420 shinsley@aroabio.com matt@nwrcommunications.com.au 64 Richard Pearse Drive, PO Box 107111, Auckland Airport, Auckland 2150, New Auckland 2022, New Zealand Zea